• Publications
  • Influence
International scoring system for evaluating prognosis in myelodysplastic syndromes.
TLDR
Compared with prior risk-based classifications, this International Prognostic Scoring System provides an improved method for evaluating prognosis in MDS and should prove useful for more precise design and analysis of therapeutic trials in this disease.
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
TLDR
An international panel to provide updated evidence- and expert opinion-based recommendations for diagnosis and management of acute myeloid leukemia in adults includes a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
TLDR
An international expert panel is provided to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials.
Revised international prognostic scoring system for myelodysplastic syndromes.
TLDR
This revised IPSS-R comprehensively integrated the numerous known clinical features into a method analyzing MDS patient prognosis more precisely than the initial IPSS and should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease.
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
TLDR
This review contains specific recommendations for the identification and management of most important complications such as the bleeding disorder, APL differentiation syndrome, QT prolongation and other ATRA- and ATO-related toxicities, as well as for molecular assessment of response to treatment.
Prognostic score including gene mutations in chronic myelomonocytic leukemia.
TLDR
A new prognostic score based on mutational status, age, hemoglobin, WBC, and platelet counts defines three groups of CMML patients with distinct outcomes that appear more discriminative than those based solely on clinical parameters.
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
TLDR
In older adult patients with low marrow blast count (20% to 30%) WHO-defined AML, azacitidine significantly prolongs OS and significantly improves several patient morbidity measures compared with CCR.
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
TLDR
In previously untreated patients with confirmed AML who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received zsitidine alone.
...
...